Financials: MYGN reaffirmed their 2023 guidance of $730-$750mn in revenue, 68%-70% gross margin, $535mn-$555mn in opex and eps of $(0.36)-($0.24). Longer term, MYGN introduced a revenue CAGR of 10%+ in 2024-2026 with HCT growing MSD. Importantly, the 10%+ long term growth forecast does not include the contribution from FirstGene or Precise MRD, they see these new products as potential upside to their forecast with contribution beginning in 2025.MYGN gave a gross margin target of 70%+ in 2026, expected to benefit from accelerating volume growth, product mix, revenue cycle management progress, and lab transition to advanced automation. They also are guiding to 2026 SG&A of 10% lower vs 2023 as a percentage of revenue with opex growing at a 5%-6% CAGR. Management noted they are in the process of addressing the challenge of zero pays, specifically targeting those claims where there are missing records from the provider or where provider records did not sufficiently support medical necessity, as they noted those are the most solvable category of claim denials.